Hikma awarded Global Generics Acquisition of the Year

London, 14 October 2015 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody’s / BB+ S&P , both stable) the fast growing multinational pharmaceutical group is pleased to announce that it was the recipient of the “Acquisition of the Year Award” at the Global Generics and Biosimilars Awards held in Madrid on 13 October 2015. The award was given in recognition of Hikma’s acquisition of Roxane Laboratories Inc. from Boehringer Ingelheim, which will transform Hikma’s non-injectables business in the US, adding complementary and well differentiated products, an attractive pipeline, proven R&D capabilities and greater overall scale.

Press Release Corporate 14 October 2015

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.